Kathleen Sullivan Email

VP, Head Biology . ChemoCentryx

Current Roles

Employees:
78
Revenue:
$34.3M
About
ChemoCentryx, Inc. discovers, develops and commercializes novel small molecule medicines for autoimmune diseases, inflammatory disorders, cancer and infectious disease. Traficet-EN(TM), the company's orally active drug for inflammatory bowel disease, will enter clinical trials in 2003. Other products include an orally active development candidate for rheumatoid arthritis and multiple sclerosis, and emerging drug candidates for cancer and cardiopulmonary inflammation. Another drug, T487, resulted from a ChemoCentryx discovery program and is expected to enter Phase II clinical trials for psoriasis in 2003 with partner Tularik Inc. Leveraging its leadership in chemokine-based drug discovery, ChemoCentryx focuses on new classes of orally active small molecules to selectively inhibit activity of the chemokine system, the "master regulator" of immune response. Based in San Carlos, California, ChemoCentryx is privately held.
ChemoCentryx Address
835 Industrial Rd
Mountain View, CA
United States
ChemoCentryx Email

Past Companies

ChemoCentryxVice President, Head of Biology
Five Prime Therapeutics, Inc.Vice President
Five Prime Therapeutics, Inc.Associate to Senior Director

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.